Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Nutrition 21 to Enter Cough/Cold Market - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Nutrition 21 to Enter Cough/Cold Market

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Expanding its product portfolio, Nutrition 21, Inc., Purchase, NY, has received an exclusive license in the U.S. from Denmark-based Provita Development ApS for Coldizin, an ingredient combination patented in the U.S. and Europe for enhancing upper-respiratory health. A patent is pending in Canada. The exclusive license allows Nutrition 21 to expand its product portfolio with a novel, clinically substantiated ingredient for the $4.5 billion U.S. cough and cold category. “Coldizin is a clinically substantiated product that shows significant results in helping people deal with upper respiratory symptoms. Its innovative blend of the bioflavonoid troxerutin and zinc provides an option for either the dietary supplement or homeopathic segments,” said William Levi, vice president, Ingredients and Special Markets, Nutrition 21.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters